The new cleanroom at our global headquarters in Salt Lake City, Utah, was designed for today's rigorous contamination control expectations, driven by EU GMP Annex 1. Learn More
Header Artwork
Header Artwork

PUBLISHED ARTICLE

The New and Improved ISO 10993-12:2021—What Is Really Changing?

Published In: MDDI Online

Every time there is an update to a standard, especially an overarching one like the ISO 10993-12 standard that covers sample preparation recommendations, it comes with a slight dose of anxiety. This is because it might mean there is now a gap between what is expected from the regulation and what was done when the testing or assessment for a medical device was originally performed. This time, however, I must say that the updated document was only slightly modified, without unexpected twists and turns, so everyone can breathe a little easier.

 

Read the Full Story in MDDI Online

 

Helin Räägel, PhD

Biocompatibility Expert

Dr. Räägel is a globally recognized expert in medical device biocompatibility. She has extensive expertise in writing biological evaluations and assessments for regulatory submissions. These documents focus on using a risk-based approach in defining the path to evaluating medical devices, with US FDA and EU regulatory bodies as the primary audience.